Skip to main content

We’ve updated our Terms & Conditions and Privacy Policy. By using this site, you agree to these terms.

Geisinger becomes the first member of Risant Health

Multiyear partnership to apply lower GI algorithms as first step in improving patient outcomes through personalized and population health strategies

DANVILLE, Pa. and TEL AVIV, IsraelMedial EarlySign™, a leader in machine learning-based solutions to aid in early detection and prevention of high-burden diseases, today announced it is partnering with Geisinger and its Steele Institute for Health Innovation to develop and deploy a suite of machine learning-based solutions to identify individuals at risk of a range of chronic and high-burden diseases.

Partnering with Geisinger’s Steele Institute for Health Innovation, EarlySign’s LGI-Flag™ solution will be deployed to help healthcare practitioners identify patients who are at risk for significant lower GI disorders. LGI-Flag is an advanced software solution that analyzes medical data, including changes in routine blood tests, to flag those who will benefit from further evaluation. Reflecting the Steele Institute’s efforts to transform healthcare delivery by implementing solutions that improve health, patient experience, care delivery and affordability, the partnership will also explore additional opportunities to benefit patients and their care providers.

“Leveraging Geisinger’s performance as a national leader in healthcare and its culture of innovation with EarlySign’s expertise in machine learning and data analytics will enable us to identify, evaluate and intervene with high-risk patients earlier,” said Karen Murphy, PhD, RN, executive vice president and chief innovation officer at Geisinger. “This collaboration will help us potentially save lives and improve the care we provide patients by deepening our experience with AI and identifying new ways to integrate it into daily clinical care."

LGI-Flag has been used in healthcare systems around the world since 2015 to identify patients at risk for lower GI disorders associated with chronic occult bleeding. The technology will form the basis for Geisinger and EarlySign to address similar opportunities with other acute and chronic diseases. The partnership will benefit from Geisinger’s innovation infrastructure, unique data assets and world-class care teams.  

“EarlySign’s technology and the LGI-Flag solution will potentially assist our teams to more quickly identify significant lower GI disorders and intervene earlier than we historically have been able to,” said Keith A. Boell, DO, associate chief quality officer at Geisinger. “We look forward to advancing our use of this technology while leveraging our experience to help more patients benefit from these life-changing medical advances.”

“We are delighted to be partnering with Geisinger, which shares our commitment to innovation and to offering the most effective care for challenging health issues,” said Ori Geva, cofounder and CEO of Medial EarlySign. “This is the first step of our ultimate goal: enabling healthcare systems to identify and connect with those high-risk patients and engage with them early enough via interventions that may prevent or delay disease progression.” 

About Medial EarlySign
Medial EarlySign helps healthcare systems with early detection and prevention of high-burden diseases. Their suite of outcome-focused software solutions (AlgoMarkers™) find subtle, early signs of high-risk patient trajectories in existing lab results and ordinary EHR data already collected in the course of routine care. EarlySign’s AlgoMarkers are currently helping clients identify patients at high risk for conditions such as lower GI disorders, prediabetic progression to diabetes, downstream diabetic complications, first coronary artery disease (CAD) and equivalent events, and chronic kidney disease (CKD).  As healthcare systems transition from volume to value-based care, EarlySign partners with health care organizations to support outcome-focused care delivery, while potentially preventing or delaying the onset of high-burden diseases, downstream complications, and their associated costs. The company’s machine learning platform has been supported by peer-reviewed research published by internationally recognized health organizations and hospitals. Founded in 2009, Medial EarlySign is headquartered in Tel Aviv, Israel with US headquarters in Boston, MA. For more information, please visit
Follow Medial EarlySign on LinkedIn: Medial EarlySign and Twitter: @MedialEarlySign

Media Relations Contact:
Ellie Hanson 

About Geisinger
Geisinger is among the nation’s leading providers of value-based care, serving 1.2 million people in urban and rural communities across Pennsylvania. Founded in 1915 by philanthropist Abigail Geisinger, the non-profit system generates $10 billion in annual revenues across 134 care sites - including 10 hospital campuses, and Geisinger Health Plan, with 600,000 members in commercial and government plans. The Geisinger College of Health Sciences educates more than 5,000 medical professionals annually and conducts more than 1,400 clinical research studies. With 26,000 employees, including 1,600 employed physicians, Geisinger is among Pennsylvania’s largest employers with an estimated economic impact of $14 billion to the state’s economy. On March 31, 2024, Geisinger became the first member of Risant Health, a new nonprofit charitable organization created to expand and accelerate value-based care across the country.  Learn more at or connect with us on Facebook, Instagram, LinkedIn and X.

geisinger placeholder
Medial EarlySign logo

For media inquires:

Matthew Van Stone
Media Relations Director

Content from General Links with modal content